Table 2.
Transplant-associated variables
| Variable | ALL, n (%) | AML, n (%) | P |
|---|---|---|---|
| Stem cell source | .31 | ||
| Marrow | 293 (79) | 260 (76) | |
| PBSC | 79 (21) | 84 (24) | |
| Conditioning regimen | <.001 | ||
| Myeloablative | 355 (95) | 296 (86) | |
| Reduced intensity | 7 (2) | 10 (3) | |
| Nonmyeloablative | 10 (3) | 38 (11) | |
| In vivo T-cell depletion | .004 | ||
| No | 295 (79) | 241 (70) | |
| Yes | 77 (21) | 103 (30) | |
| GVHD prophylaxis | .12 | ||
| Tacrolimus + MMF ± others | 22 (6) | 31 (9) | |
| Tacrolimus + MTX ± others, except MMF | 173 (47) | 137 (40) | |
| Tacrolimus + others, except MTX, MMF | 10 (3) | 7 (2) | |
| Tacrolimus alone | 6 (2) | 1 (<1) | |
| CSA + MMF ± others, except tacrolimus | 25 (7) | 28 (8) | |
| CSA + MTX ± others, except tacrolimus, MMF | 119 (32) | 124 (36) | |
| CSA + others, except tacrolimus, MTX, MMF | 11 (3) | 6 (2) | |
| CSA alone | 6 (2) | 10 (3) |
CSA, cyclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate; PBSC, peripheral blood stem cell.